Trillium Asset Management LLC Invests $3.23 Million in DexCom, Inc. $DXCM

Key Points

• Trillium Asset Management acquired 47,881 DexCom shares worth approximately $3.23 million during the second quarter. Institutional investors collectively own 97.75% of the company.
• DexCom reported quarterly EPS of $0.70, beating estimates of $0.61, while revenue rose 13.1% year over year to $1.31 billion. The company posted a 20.12% net margin and 35.94% return on equity.
• Analysts maintain a favorable outlook, with a consensus rating of “Moderate Buy” and an average price target of $88.71; however, insiders have sold 73,035 shares worth about $5.45 million over the past 90 days.

Trillium Asset Management LLC acquired a new stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 47,881 shares of the medical device company's stock, valued at approximately $3,225,000.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Reflection Asset Management acquired a new position in shares of DexCom during the 4th quarter worth about $25,000. Ascentis Independent Advisors bought a new stake in shares of DexCom in the 1st quarter valued at about $25,000. MCF Advisors LLC acquired a new stake in shares of DexCom in the 4th quarter valued at approximately $32,000. Wellington Grp LLC raised its position in shares of DexCom by 778.7% in the 1st quarter. Wellington Grp LLC now owns 536 shares of the medical device company's stock valued at $34,000 after acquiring an additional 475 shares during the period. Finally, DV Equities LLC bought a new position in DexCom during the 4th quarter worth approximately $36,000. Institutional investors own 97.75% of the company's stock.

DexCom Stock Performance

Shares of DXCM opened at $90.22 on Friday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.43 and a current ratio of 1.73. DexCom, Inc. has a twelve month low of $54.11 and a twelve month high of $91.96. The firm's 50 day moving average price is $77.15 and its two-hundred day moving average price is $70.79. The firm has a market cap of $34.05 billion, a P/E ratio of 35.66, a PEG ratio of 1.52 and a beta of 1.41.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The medical device company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.61 by $0.09. The company had revenue of $1.31 billion during the quarter, compared to the consensus estimate of $1.29 billion. DexCom had a net margin of 20.12% and a return on equity of 35.94%. The firm's revenue was up 13.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.48 earnings per share. On average, analysts forecast that DexCom, Inc. will post 2.64 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

DXCM has been the subject of a number of analyst reports. Citigroup restated a "buy" rating and set a $88.00 price objective (up from $84.00) on shares of DexCom in a report on Friday, July 31st. Truist Financial set a $93.00 target price on shares of DexCom and gave the stock a "buy" rating in a report on Friday, July 31st. William Blair raised shares of DexCom to a "strong-buy" rating in a research report on Friday, May 15th. Canaccord Genuity Group set a $90.00 price target on shares of DexCom and gave the company a "buy" rating in a report on Monday, August 3rd. Finally, Benchmark upped their price objective on shares of DexCom from $77.00 to $82.00 and gave the company a "buy" rating in a research report on Friday, July 31st. Two analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $88.71.

Insider Transactions at DexCom

In other DexCom news, Director Mark G. Foletta sold 4,000 shares of DexCom stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $74.13, for a total value of $296,520.00. Following the sale, the director owned 52,852 shares of the company's stock, valued at $3,917,918.76. This trade represents a 7.04% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Jon Coleman sold 4,912 shares of the business's stock in a transaction dated Wednesday, June 3rd. The shares were sold at an average price of $73.00, for a total value of $358,576.00. Following the completion of the sale, the executive vice president owned 100,361 shares in the company, valued at approximately $7,326,353. This trade represents a 4.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 73,035 shares of company stock worth $5,446,673 in the last 90 days. Company insiders own 0.28% of the company's stock.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company's offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source